已发表论文

肿瘤和T细胞中 SMAD4 突变和异常表达的后果

 

Authors Wan R, Feng J, Tang L

Received 17 December 2020

Accepted for publication 18 March 2021

Published 13 April 2021 Volume 2021:14 Pages 2531—2540

DOI https://doi.org/10.2147/OTT.S297855

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Leo Jen-Liang Su

Abstract: SMAD4 is a typical tumor suppressor in the TGF-β signaling pathway. In human cancers, SMAD4 is frequently mutated and inactivated. In recent years, the consequences of mutations and inactivation of SMAD4 are gradually becoming clearer. Most of the mutations have negative consequences and reduce the chances of survival of their carriers. Loss of SMAD4 functions due to mutations or abnormal expression can suppress the inhibition of tumor growth and support the tumor progression. Functions of SMAD4 and its variants in T cells are being studied extensively, to better understand the SMAD4 functions in T cells. In this review, we mainly discuss the recently reported consequences of mutations and abnormal expression of SMAD4 in tumors, and the effects of loss, deficiency or mutation of SMAD4 and its T cells, to show the use of SMAD4 mutations in cancer diagnosis and therapeutic strategies.
Keywords: SMAD4, mutation, abnormal expression, T cell, TGF-β